Stefan Ilic

Mr. Stefan Ilic

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
SIStefan Ilic
Stefan Ilic
SCShira Cohen
Shira Cohen
MSMeenakshi Singh
Meenakshi Singh
BTBenjamin Tam
Benjamin Tam
ADAdi Dayan
Adi Dayan
BABarak Akabayov
Barak Akabayov
The bacterial primase—an essential component in the replisome—is a promising but underexploited target for novel antibiotic drugs. Bacterial primases have a markedly different structure than the human primase. Inhibition of primase activity is expected to selectively halt bacterial DNA replication. Evidence is growing that halting DNA replication has a bacteriocidal effect. Therefore, inhibitors of DNA primase could provide antibiotic agents. Compounds that inhibit bacterial DnaG primase have been developed using different approaches. In this paper, we provide an overview of the current literature on DNA primases as novel drug targets and the methods used to find their inhibitors. Although few inhibitors have been identified, there are still challenges to develop inhibitors that can efficiently halt DNA replication and may be applied in a clinical setting.

26 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMeenakshi Singh
Meenakshi Singh
SIStefan Ilic
Stefan Ilic
BTBenjamin Tam
Benjamin Tam
YBYesmin Ben-Ishay
Yesmin Ben-Ishay
RDRikeshwer Prasa Dewangan
Rikeshwer Prasa Dewangan
BABarak Akabayov
Barak Akabayov
Mycobacterium tuberculosis(Mtb) is a pathogenic bacterium and a causative agent of tuberculosis (TB), a disease that kills more than 1.5 million people worldwide annually. One of the main reasons for this high mortality rate is the evolution of newMtbstrains that are resistant to available antibiotics. Therefore, new therapeutics for TB are in constant demand. Here we report the development of such inhibitors that target two DNA replication enzymes ofMtb, namely DnaG primase and DNA gyrase, which share a conserved TOPRIM fold near the inhibitors’ binding site. The molecules were developed on the basis of previously reported inhibitors for T7 DNA primase that bind near the TOPRIM fold. In order to improve the physicochemical properties of the molecules as well as their inhibitory effect on primase and gyrase, 49 novel compounds were synthesized as potential drug candidates in three stages of optimization. The last stage of chemical optimization yielded two novel inhibitors for the fast-growing nonpathogenic modelMycobacterium smegmatis(Msmg).